Partner Headlines - ARNA

  1. CNBC's Stock Pops & Drops From January 21

    Benzinga
  2. Mid-Afternoon Market Update: Alnylam Pharmaceuticals Drops Following ...

    Benzinga
  3. 4 More Biotech Secondaries Traders Are Watching

    Benzinga
  4. Mid-Day Market Update: U.S. Stocks Surge; Netflix Shares Jump ...

    Benzinga
  5. Mid-Morning Market Update: Markets Mixed; UnitedHealth Profit ...

    Benzinga
  6. Morning Market Losers

    Benzinga
  7. Wednesday Morning Movers: Netflix Flying High

    Benzinga
  8. Arena Pharmaceuticals Announces Agreement to Sell Common Stock

    Benzinga
  9. Benzinga's Top #PreMarket Losers

    Benzinga
  10. Tuesday's After-Hours Movers: Netflix Leads The Pack

    Benzinga
  11. 5 Obesity Stocks Investors Are Watching

    Benzinga
  12. Biotechs Presenting At The J.P. Morgan Healthcare Conference: ...

    Benzinga
  13. Mid-Afternoon Market Update: Dow Jumps Over 200 Points After ...

    Benzinga
  14. Mid-Day Market Update: J C Penney Jumps On Strong Holiday Sales; ...

    Benzinga
  15. Mid-Morning Market Update: Markets Surge; Monsanto Profit Tops ...

    Benzinga
  16. Morning Market Gainers

    Benzinga
  17. Benzinga's Top #PreMarket Gainers

    Benzinga
  18. 4 Potential Blockbuster Drugs The FDA Just Approved

    IBD
  19. Orexigen Therapeutics Gains On Diet Pill Nod From European Committee

    Benzinga
  20. Pharmaceutical Stocks In Play Following Merck/Cubist Deal

    Benzinga
  21. What's Driving Orexigen Therapeutics Higher?

    Benzinga
  22. Benzinga's Top #PreMarket Gainers

    Benzinga
  23. Arena Pharma Reports Q3 EPS Loss $0.05, Revenues Of $8.16M Vs. ...

    Benzinga
  24. Earnings Scheduled For November 3, 2014

    Benzinga
  25. 3 Pharma Companies Fighting Obesity

    Benzinga
  26. Benzinga's Top #PreMarket Gainers

    Benzinga
  27. Bank Of America Q3 Small & Mid-Cap Biotech Preview

    Benzinga
  28. Eisai And Arena Pharmaceuticals Announce Publication Of Pooled ...

    Benzinga
  29. Earnings Scheduled For August 1, 2014

    Benzinga
  30. Benzinga's Top #PreMarket Losers

    Benzinga
  31. Markets Marginally Lower Ahead Of Earnings Season

    Benzinga
  32. Arena Pharmaceutical Shares Dive On News CEO Sold 40% Of His ...

    Benzinga
  33. Benzinga's Top #PreMarket Losers

    Benzinga
  34. Events Scheduled for Week of Jun. 16th to Jun. 20th

    Benzinga
  35. FDA delays Orexigen drug

    IBD
  36. Is Arena Pharmaceuticals A Biotech Stock To Watch?

    Benzinga
  37. Orexigen Obesity Drug Decision Delayed By FDA

    IBD
  38. Orexigen Shares Plummet Following FDA Decision; Competition Gets ...

    Benzinga
  39. Arena Pharma Posts Q1 Loss Of $0.12/Share, Misses By ~$0.02/Share

    Benzinga
  40. Earnings Scheduled For May 12, 2014

    Benzinga
  41. Mornings Movers for Feb. 28, 2014: CETV, OTVI, MELI, REGI, GALE ...

    Benzinga
  42. Benzinga's Top #PreMarket Losers

    Benzinga
  43. Earnings Scheduled For February 27, 2014

    Benzinga
  44. Bad Earnings Weigh In On Diet Stocks

    Benzinga
  45. Top Trending Tickers On StockTwits For February 14

    Benzinga
  46. #PreMarket Primer: Friday, February 14: A Turnaround

    Benzinga
  47. Arena Pharmaceuticals Announces Filing for Marketing Authorization ...

    Benzinga
  48. Celgene To Release Earnings At J.P. Morgan Event Mon.

    IBD
  49. The Top Five Drug Launches Of 2013

    IBD
  50. (ARNA) Initiated with a Buy, (ICLD, FONR) Strong Performance ...

    GuruFocus
  51. Benzinga's Top #PreMarket Gainers

    Benzinga
  52. Market Wrap For November 11: Relative Quiet as Traders and Investors ...

    Benzinga
  53. Market Wrap For November 8: Markets Erase Thursday's Losses; ...

    Benzinga
  54. Arena Pharmaceuticals, Eisai Expand Marketing and Supply Agreement ...

    Benzinga
  55. Nasdaq Leads Stocks Lower; Twitter IPO Opens To 80% Gain

    IBD
  56. How Arena’s “$3 Billion” Belviq Withered

    YCharts
  57. Benzinga's Top #PreMarket Losers

    Benzinga
  58. Market Wrap For Tuesday, October 15: Earnings Reports And White ...

    Benzinga
  59. Mid-Afternoon Market Update: Tumi Holdings Rises Amid Market ...

    Benzinga
  60. Mid-Morning Market Update: Markets Slip; Citigroup Profit Misses ...

    Benzinga
  61. UPDATE: Arena Says Eisai Will Double BELVIQ Sales Force to 4 ...

    Benzinga
  62. Vivus Weighs In As a Leader for Diet Pills, Cowen Upgrades and ...

    Benzinga
  63. Obesity Drug Stocks Jump As Cowen Gets Bullish

    IBD
  64. Benzinga's Top Pre-Market Losers

    Benzinga
  65. Market Wrap For September 30: Debt Ceiling And Government Shutdown ...

    Benzinga
  66. Mid-Afternoon Market Update: Mellanox Rallies As Market Remains ...

    Benzinga
  67. Mid-Day Market Update: Dow Falls Over 100 Points; Active Network ...

    Benzinga
  68. Mid-Morning Market Update: Markets Open Lower; Cal-Maine Q1 Net ...

    Benzinga
  69. UPDATE: Credit Suisse Lowers PT on Arena Pharmaceuticals Following ...

    Benzinga
  70. Arena Pharma Offers Update on Eisai Launch of BELVIQ, Says Placing ...

    Benzinga
  71. Stocks Hitting 52-Week Lows

    Benzinga
  72. BMO Considers Recent Sales Data on Arena's Belviq, Maintains ...

    Benzinga
  73. CEO Shift Aside, Whose Weight-Loss Pill’s Ahead

    YCharts
  74. Stocks Hitting 52-Week Lows

    Benzinga
  75. Stocks Hitting 52-Week Lows

    Benzinga
  76. Arena Pharma Reports Closing of Phase 1b Clinical Trial for APD811

    Benzinga
  77. Short Interest In Celgene, Onyx Continues To Shrink (CELG, ONXX, ...

    Benzinga
  78. It's Hard to Sell a Pill That Nobody's Heard Of

    YCharts
  79. Weekly Preview: Earnings Season Continues, Fed In Focus, Economic ...

    Benzinga
  80. Short Interest in Pharmacyclics Plunges (AMGN, ONXX, PCYC)

    Benzinga
  81. Short Interest Swings in Biotech Stocks (AMGN, CELG, ONXX)

    Benzinga
  82. Short Interest Swings in Biotech Stocks (BIIB, CELG, VVUS)

    Benzinga
  83. Mid-Afternoon Market Update: Markets All Green, Research in Motion ...

    Benzinga
  84. Mid-Day Market Update: GenCorp Rises, Markets Erasing Losses

    Benzinga
  85. Mid-Morning Market Update: Verizon Misses Big on Earnings, Research ...

    Benzinga
  86. Vivus fell 4.2% to 13.72

    IBD
  87. Vivus Stock Drops On Downgrade; Rival Arena Rises

    IBD
  88. Measuring Social Network Buzz Over Pharma Stocks

    YCharts
  89. Vivus Stock Jumps On Latest Qsymia Shipment Numbers

    IBD
  90. Short Interest Swings in Biotech Stocks (CELG, GILD, REGN)

    Benzinga
  91. Benzinga's Top Pre-Market Gainers

    Benzinga
  92. The Best Small Cap Performers of 2012

    Benzinga
  93. Vivus Soars On Qsymia Anti-Obesity Drug Prescriptions

    IBD
  94. Acadia Pharma Rockets Higher on Study Results

    Benzinga
  95. Vivus Stock Soars As Aetna Adds Qsymia To Coverage

    IBD
  96. Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)

    Benzinga
  97. Arena Pharmaceuticals Inc. Reports Operating Results (10-Q)

    GuruFocus
  98. UPDATE: Jefferies & Company Reiterates Buy Rating, Lowers PT ...

    Benzinga
  99. Vivus Earnings Miss Estimates; Arena Waits In Wings

    IBD
  100. Short Interest Swings in Biotech Stocks (BIIB, GILD, VVUS)

    Benzinga
Trading Center